The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long COVID when administered outside of an infection. Administration of Paxlovid ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer PFE.N COVID-19 treatment Paxlovid, Bristol Myers Squibb's BMY.N cancer cell therapies and vaccines ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

11,358,953 in the manufacture, use, and sale of Paxlovid. The company said that in a ruling over a summary judgment motion filed by Pfizer (PFE), the court determined that its ‘953 patent was ...

Case series of 13 Long COVID patients aged 25-55 examined the impact of extended Paxlovid courses (7.5-30 days). Some reported significant relief, others saw no change, and one experienced severe ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Valued at a market cap of $152.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company dedicated to advancing ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, ...